C83.60 Undifferentiated (diffuse) non-Hodgkin's lymphoma, unspecified site

Name of the Condition

• Undifferentiated (diffuse) non-Hodgkin's lymphoma, unspecified site
• Also known as ICD-10 code C83.60

Summary

Undifferentiated (diffuse) non-Hodgkin's lymphoma is a subtype of non-Hodgkin lymphoma characterized by the malignant proliferation of lymphoid cells that lack distinct differentiation or follicular structure. It typically involves abnormal growth of B-cells or T-cells in lymph nodes or other lymphoid tissues, with a diffuse pattern of spread. This condition is part of the broader category of non-follicular lymphomas and may present with variable clinical behavior depending on the specific subtype.

Causes

The exact cause of undifferentiated (diffuse) non-Hodgkin's lymphoma remains unknown. It is thought to involve genetic mutations or abnormalities in lymphoid cell development, though specific triggers are not well-defined. Research suggests potential links to immune system dysregulation or prior infections, but no definitive etiology has been established.

Risk Factors

• Age: More common in older adults.
• Family history of lymphoma.
• Prior exposure to radiation or certain chemicals.
• Chronic infections, such as hepatitis C or HIV.
• Immunosuppressive conditions or treatments.

Symptoms

• Swollen, painless lymph nodes.
• Unexplained weight loss.
• Fever.
• Night sweats.
• Fatigue.
• Loss of appetite.

Diagnosis

Diagnosis involves a combination of physical examination, imaging tests (e.g., CT or PET scans) to identify affected areas, biopsy of lymph nodes or tissues for laboratory analysis, and blood tests to assess overall health and detect abnormal cell markers. Pathological evaluation is critical to confirm the undifferentiated (diffuse) subtype and rule out other lymphoma types.

Treatment Options

• Chemotherapy: Systemic drugs to target and kill cancer cells.
• Immunotherapy: Uses the body's immune system to fight cancer cells.
• Radiation Therapy: High-energy radiation to target localized disease.
• Stem Cell Transplant: For eligible patients with aggressive disease.

Prognosis and Follow-Up

Prognosis varies based on factors such as age, overall health, and disease stage. Regular follow-up with imaging and blood tests is essential to monitor for recurrence or progression. Treatment response and long-term outcomes depend on individual patient characteristics and subtype-specific behavior.

Complications

• Disease progression or transformation to a more aggressive subtype.
• Infection due to weakened immune system.
• Organ dysfunction from lymphoma infiltration.
• Treatment-related side effects (e.g., chemotherapy toxicity).

Lifestyle & Prevention

• Maintain a balanced diet and regular exercise to support overall health.
• Avoid known carcinogens, such as tobacco and excessive alcohol.
• Practice good hygiene to reduce infection risk.
• Stay up-to-date with vaccinations, as recommended by a healthcare provider.

When to Seek Professional Help

Seek medical attention if you experience persistent swollen lymph nodes, unexplained weight loss, fever, night sweats, or fatigue. Early evaluation is important for timely diagnosis and management.

Tips for Medical Coders

When coding for C83.60, ensure documentation specifies "undifferentiated (diffuse)" and "unspecified site" to align with the code's definition. Verify that the diagnosis is confirmed by pathological review, as this supports accurate coding. Document any relevant clinical details, such as imaging findings or biopsy results, to justify the code assignment.